0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.00%IV89.75%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier30DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma105.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Voyager Therapeutics Stock Discussion
Very oversold, less than 1% profitable positions, undervalued by all except p/e which is still under market avg.
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
Looks like 6 holds the big buy but we shall see. Don't expect it to get much lower.
Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
No comment yet